{"PMID_32294323": [{"sent_idx": 0, "char_start": 0, "char_end": 105, "sent_text": "Esophageal cancers comprise adenocarcinoma and squamous cell carcinoma, two distinct histologic subtypes."},
  {"sent_idx": 1, "char_start": 106, "char_end": 177, "sent_text": "Both are difficult to treat and among the deadliest human malignancies."},
  {"sent_idx": 2, "char_start": 178, "char_end": 374, "sent_text": "We describe protocols to initiate, grow, passage, and characterize patient-derived organoids (PDO) of esophageal cancers, as well as squamous cell carcinomas of oral/head-and-neck and anal origin."},
  {"sent_idx": 3, "char_start": 375, "char_end": 541, "sent_text": "Formed rapidly (<14 days) from a single-cell suspension embedded in basement membrane matrix, esophageal cancer PDO recapitulate the histology of the original tumors."},
  {"sent_idx": 4, "char_start": 542, "char_end": 794, "sent_text": "Additionally, we provide guidelines for morphological analyses and drug testing coupled with functional assessment of cell response to conventional chemotherapeutics and other pharmacological agents in concert with emerging automated imaging platforms."},
  {"sent_idx": 5, "char_start": 795, "char_end": 1023, "sent_text": "Predicting drug sensitivity and potential therapy resistance mechanisms in a moderate-to-high throughput manner, esophageal cancer PDO are highly translatable in personalized medicine for customized esophageal cancer treatments."}, {"sent_idx": 6, "char_start": 1024, "char_end": 1057, "sent_text": "\u00a9 2020 by John Wiley & Sons, Inc."}, {"sent_idx": 7, "char_start": 1058, "char_end": 1581, "sent_text": "Basic Protocol 1: Generation of esophageal cancer PDO Basic Protocol 2: Propagation and cryopreservation of esophageal cancer PDO Basic Protocol 3: Imaged-based monitoring of organoid size and growth kinetics Basic Protocol 4: Harvesting esophageal cancer PDO for histological analyses Basic Protocol 5: PDO content analysis by flow cytometry Basic Protocol 6: Evaluation of drug response with determination of the half-inhibitory concentration (IC50 ) Support Protocol: Production of RN in HEK293T cell conditioned medium."}], "PMID_33421710": [{"sent_idx": 0, "char_start": 0, "char_end": 60, "sent_text": "Bone is the most frequent metastasis site for breast cancer."}, {"sent_idx": 1, "char_start": 61, "char_end": 168, "sent_text": "As well as dramatically increasing disease burden, bone metastases are also an indicator of poor prognosis."}, {"sent_idx": 2, "char_start": 169, "char_end": 334, "sent_text": "One of the main challenges in investigating bone metastasis in breast cancer is engineering in vitro models that replicate the features of in vivo bone environments."}, {"sent_idx": 3, "char_start": 335, "char_end": 462, "sent_text": "Such in vitro models ideally enable the biology of the metastatic cells to mimic their in vivo behavior as closely as possible."}, {"sent_idx": 4, "char_start": 463, "char_end": 629, "sent_text": "Here, taking benefit of cutting-edge technologies both in microfabrication and cancer cell biology, we have developed an in vitro breast cancer bone-metastasis model."}, {"sent_idx": 5, "char_start": 630, "char_end": 818, "sent_text": "To do so we first 3D printed a bone scaffold that reproduces the trabecular architecture and that can be conditioned with osteoblast-like cells, a collagen matrix, and mineralized calcium."}, {"sent_idx": 6, "char_start": 819, "char_end": 933, "sent_text": "We thus demonstrated that this device offers an adequate soil to seed primary breast cancer bone metastatic cells."}, {"sent_idx": 7, "char_start": 934, "char_end": 1200, "sent_text": "In particular, patient-derived xenografts being considered as a better approach than cell lines to achieve clinically relevant results, we demonstrate the ability of this biomimetic bone niche model to host patient-derived xenografted metastatic breast cancer cells."}, {"sent_idx": 8, "char_start": 1201, "char_end": 1378, "sent_text": "These patient-derived xenograft cells show a long-term survival in the bone model and maintain their cycling propensity, and exhibit the same modulated drug response as in vivo."}, {"sent_idx": 9, "char_start": 1379, "char_end": 1546, "sent_text": "This experimental system enables access to the idiosyncratic features of the bone microenvironment and cancer bone metastasis, which has implications for drug testing."}], "PMID_26695443": [{"sent_idx": 0, "char_start": 0, "char_end": 91, "sent_text": "Oestrogen receptor-negative (ER-) breast cancer is intrinsically sensitive to chemotherapy."}, {"sent_idx": 1, "char_start": 92, "char_end": 177, "sent_text": "However, tumour response is often incomplete, and relapse occurs with high frequency."}, {"sent_idx": 2, "char_start": 178, "char_end": 481, "sent_text": "The aim of this work was to analyse the molecular characteristics of residual tumours and early response to chemotherapy in patient-derived xenografts (PDXs) of breast cancer.Gene and protein expression profiles were analysed in a panel of ER- breast cancer PDXs before and after chemotherapy treatment."}, {"sent_idx": 3, "char_start": 482, "char_end": 842, "sent_text": "Tumour and stromal interferon-gamma expression was measured in xenografts lysates by human and mouse cytokine arrays, respectively.The analysis of residual tumour cells in chemo-responder PDX revealed a strong overexpression of IFN-inducible genes, induced early after AC treatment and associated with increased STAT1 phosphorylation, DNA-damage and apoptosis."}, {"sent_idx": 4, "char_start": 843, "char_end": 943, "sent_text": "No increase in IFN-inducible gene expression was observed in chemo-resistant PDXs upon chemotherapy."}, {"sent_idx": 5, "char_start": 944, "char_end": 1170, "sent_text": "Overexpression of IFN-related genes was associated with human IFN-\u03b3 secretion by tumour cells.Treatment-induced activation of the IFN/STAT1 pathway in tumour cells is associated with chemotherapy response in ER- breast cancer."}, {"sent_idx": 6, "char_start": 1171, "char_end": 1333, "sent_text": "Further validations in prospective clinical trials will aim to evaluate the usefulness of this signature to assist therapeutic strategies in the clinical setting."}], "PMID_31761724": [{"sent_idx": 0, "char_start": 0, "char_end": 219, "sent_text": "Accumulating evidence indicates that patient-derived organoids (PDOs) can predict drug responses in the clinic, but the ability of PDOs to predict responses to chemoradiation in cancer patients remains an open question."}, {"sent_idx": 1, "char_start": 220, "char_end": 406, "sent_text": "Here we generate a living\u00a0organoid biobank from patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NACR) enrolled in a phase III clinical trial."}, {"sent_idx": 2, "char_start": 407, "char_end": 563, "sent_text": "Our co-clinical trial data confirm that rectal cancer organoids (RCOs) closely recapitulate the pathophysiology and genetic changes of corresponding tumors."}, {"sent_idx": 3, "char_start": 564, "char_end": 703, "sent_text": "Chemoradiation responses in patients are highly matched to RCO responses, with 84.43% accuracy, 78.01% sensitivity, and 91.97% specificity."}, {"sent_idx": 4, "char_start": 704, "char_end": 849, "sent_text": "These data imply that PDOs predict LARC patient responses in the clinic and may represent a companion diagnostic tool in rectal cancer treatment."}], "PMID_28561063": [{"sent_idx": 0, "char_start": 0, "char_end": 137, "sent_text": "Stromal content heavily impacts the transcriptional classification of colorectal cancer (CRC), with clinical and biological implications."}, {"sent_idx": 1, "char_start": 138, "char_end": 276, "sent_text": "Lineage-dependent stromal transcriptional components could therefore dominate over more subtle expression traits inherent to cancer cells."}, {"sent_idx": 2, "char_start": 277, "char_end": 514, "sent_text": "Since in patient-derived xenografts (PDXs) stromal cells of the human tumour are substituted by murine counterparts, here we deploy human-specific expression profiling of CRC PDXs to assess cancer-cell intrinsic transcriptional features."}, {"sent_idx": 3, "char_start": 515, "char_end": 1047, "sent_text": "Through this approach, we identify five CRC intrinsic subtypes (CRIS) endowed with distinctive molecular, functional and phenotypic peculiarities: (i) CRIS-A: mucinous, glycolytic, enriched for microsatellite instability or KRAS mutations; (ii) CRIS-B: TGF-\u03b2 pathway activity, epithelial-mesenchymal transition, poor prognosis; (iii) CRIS-C: elevated EGFR signalling, sensitivity to EGFR inhibitors; (iv) CRIS-D: WNT activation, IGF2 gene overexpression and amplification; and (v) CRIS-E: Paneth cell-like phenotype, TP53 mutations."}, {"sent_idx": 4, "char_start": 1048, "char_end": 1249, "sent_text": "CRIS subtypes successfully categorize independent sets of primary and metastatic CRCs, with limited overlap on existing transcriptional classes and unprecedented predictive and prognostic performances."}], "PMID_35410383": [{"sent_idx": 0, "char_start": 0, "char_end": 88, "sent_text": "The persistence of cancer cells resistant to therapy remains a major clinical challenge."}, {"sent_idx": 1, "char_start": 89, "char_end": 218, "sent_text": "In triple-negative breast cancer, resistance to chemotherapy results in the highest recurrence risk among breast cancer subtypes."}, {"sent_idx": 2, "char_start": 219, "char_end": 341, "sent_text": "The drug-tolerant state seems largely defined by nongenetic features, but the underlying mechanisms are poorly understood."}, {"sent_idx": 3, "char_start": 342, "char_end": 574, "sent_text": "Here, by monitoring epigenomes, transcriptomes and lineages with single-cell resolution, we show that the repressive histone mark H3K27me3 (trimethylation of histone\u2009H3 at lysine\u200927) regulates cell fate at the onset of chemotherapy."}, {"sent_idx": 4, "char_start": 575, "char_end": 791, "sent_text": "We report that a persister expression program is primed with both H3K4me3 (trimethylation of histone\u2009H3 at lysine\u20094) and H3K27me3 in unchallenged cells, with H3K27me3 being the lock to its transcriptional activation."}, {"sent_idx": 5, "char_start": 792, "char_end": 903, "sent_text": "We further demonstrate that depleting H3K27me3 enhances the potential of cancer cells to tolerate chemotherapy."}, {"sent_idx": 6, "char_start": 904, "char_end": 1067, "sent_text": "Conversely, preventing H3K27me3 demethylation simultaneously to chemotherapy inhibits the transition to a drug-tolerant state, and delays tumor recurrence in vivo."}, {"sent_idx": 7, "char_start": 1068, "char_end": 1181, "sent_text": "Our results highlight how chromatin landscapes shape the potential of cancer cells to respond to initial therapy."}], "PMID_25444907": [{"sent_idx": 0, "char_start": 0, "char_end": 162, "sent_text": "Molecular annotated patient-derived xenograft (PDX) models are useful for the preclinical investigation of anticancer drugs and individualized anticancer therapy."}, {"sent_idx": 1, "char_start": 163, "char_end": 371, "sent_text": "We established 23 PDXs from 88 surgical specimens of lung cancer patients and determined gene mutations in these PDXs and their paired primary tumors by ultradeep exome sequencing on 202 cancer-related genes."}, {"sent_idx": 2, "char_start": 372, "char_end": 536, "sent_text": "The numbers of primary tumors with deleterious mutations in TP53, KRAS, PI3KCA, ALK, STK11, and EGFR were 43.5%, 21.7%, 17.4%, 17.4%, 13.0%, and 8.7%, respectively."}, {"sent_idx": 3, "char_start": 537, "char_end": 684, "sent_text": "Other genes with deleterious mutations in \u22653 (13.0%) primary tumors were MLL3, SETD2, ATM, ARID1A, CRIPAK, HGF, BAI3, EP300, KDR, PDGRRA and RUNX1."}, {"sent_idx": 4, "char_start": 685, "char_end": 879, "sent_text": "Of 315 mutations detected in the primary tumors, 293 (93%) were also detected in their corresponding PDXs, indicating that PDXs have the capacity to recapitulate the mutations in primary tumors."}, {"sent_idx": 5, "char_start": 880, "char_end": 1142, "sent_text": "Nevertheless, a substantial number of mutations had higher allele frequencies in the PDXs than in the primary tumors, or were not detectable in the primary tumor, suggesting the possibility of tumor cell enrichment in PDXs or heterogeneity in the primary tumors."}, {"sent_idx": 6, "char_start": 1143, "char_end": 1249, "sent_text": "The molecularly annotated PDXs generated from this study could be useful for future translational studies."}], "PMID_36058001": [{"sent_idx": 0, "char_start": 0, "char_end": 144, "sent_text": "There is no effective method to predict chemotherapy response and postoperative prognosis of colorectal cancer liver metastasis (CRLM) patients."}, {"sent_idx": 1, "char_start": 145, "char_end": 218, "sent_text": "Patient-derived organoid (PDO) has become an important preclinical model."}, {"sent_idx": 2, "char_start": 219, "char_end": 359, "sent_text": "Herein, a living biobank with 50 CRLM organoids derived from primary tumors and paired liver metastatic lesions is successfully constructed."}, {"sent_idx": 3, "char_start": 360, "char_end": 596, "sent_text": "CRLM PDOs from the multiomics levels (histopathology, genome, transcriptome and single-cell sequencing) are comprehensively analyzed and confirmed that this organoid platform for CRLM could capture intra- and interpatient heterogeneity."}, {"sent_idx": 4, "char_start": 597, "char_end": 785, "sent_text": "The chemosensitivity data in vitro reveal the potential value of clinical application for PDOs to predict chemotherapy response (FOLFOX or FOLFIRI) and clinical prognosis of CRLM patients."}, {"sent_idx": 5, "char_start": 786, "char_end": 889, "sent_text": "Taken together, CRLM PDOs can be utilized to deliver a potential application for personalized medicine."}], "PMID_35802820": [{"sent_idx": 0, "char_start": 0, "char_end": 53, "sent_text": "Kidney cancer is one of the most common solid tumors."}, {"sent_idx": 1, "char_start": 54, "char_end": 364, "sent_text": "The advancement of human kidney cancer research and treatment has been hindered by a lack of research models that faithfully recapitulate the diversity of the disease.We established an effective three-dimensional culture system for generating kidney cancer organoids from clinical renal cell carcinoma samples."}, {"sent_idx": 2, "char_start": 365, "char_end": 528, "sent_text": "Renal cell carcinoma (RCC) organoids were characterized by H&E staining, immunofluorescence, whole-exome sequencing, RNA sequencing and single-cell RNA sequencing."}, {"sent_idx": 3, "char_start": 529, "char_end": 937, "sent_text": "The use of RCC organoids in personalized cancer therapy was assessed by testing their responses to treatment drugs and chimeric antigen receptor T cells.Using this organoid culture system, 33 kidney cancer organoid lines from common kidney cancer subtypes, including clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), and chromophobe renal cell carcinoma (chRCC), were generated."}, {"sent_idx": 4, "char_start": 938, "char_end": 1075, "sent_text": "RCC organoids preserved the histological architectures, mutational landscapes, and transcriptional profile of the parental tumor tissues."}, {"sent_idx": 5, "char_start": 1076, "char_end": 1168, "sent_text": "Single-cell RNA-sequencing revealed inter- and intra-tumoral heterogeneity in RCC organoids."}, {"sent_idx": 6, "char_start": 1169, "char_end": 1414, "sent_text": "RCC organoids allowed for in vitro drug screening and provided a tool for assessing the efficacy of chimeric antigen receptor T cells.Patient-derived RCC organoids are valuable pre-clinical models for academic research and personalized medicine."}], "PMID_34011980": [{"sent_idx": 0, "char_start": 0, "char_end": 317, "sent_text": "Patient-derived xenograft (PDX) and their xenograft-derived organoid (XDO) models that recapitulate the genotypic and phenotypic landscape of patient cancers could help to advance research and lead to improved clinical management.\u00a0PDX models were established from 276 pancreato-duodenal and biliary cancer resections."}, {"sent_idx": 1, "char_start": 318, "char_end": 463, "sent_text": "Initial, passage 0 (P0) engraftment rates were 59% (118/199) for pancreatic, 86% (25/29) for duodenal, and 35% (17/48) for biliary ductal tumors."}, {"sent_idx": 2, "char_start": 464, "char_end": 689, "sent_text": "Pancreatic ductal adenocarcinoma (PDAC), had a P0 engraftment rate of 62% (105/169).\u00a0KRAS\u00a0mutant and wild-type PDAC models were molecularly profiled, and XDO models were generated to perform initial drug response evaluations."}, {"sent_idx": 3, "char_start": 690, "char_end": 901, "sent_text": "Subsets of PDAC PDX models showed global copy number variants and gene expression profiles that were retained with serial passaging, and they showed a spectrum of somatic mutations represented in patient tumors."}, {"sent_idx": 4, "char_start": 902, "char_end": 971, "sent_text": "PDAC XDO models were established, with a success rate of 71% (10/14)."}, {"sent_idx": 5, "char_start": 972, "char_end": 1054, "sent_text": "Pathway activation of KRAS-MAPK in PDXs was independent of\u00a0KRAS\u00a0mutational status."}, {"sent_idx": 6, "char_start": 1055, "char_end": 1230, "sent_text": "Four wild-type KRAS models were characterized by one with\u00a0EGFR\u00a0(L747-P753 del), two with BRAF alterations (N486_P490del or V600E), and one with triple negative\u00a0KRAS/EGFR/BRAF."}, {"sent_idx": 7, "char_start": 1231, "char_end": 1311, "sent_text": "Model OCIP256, characterized by BRAF (N486-P490 del), had activated phospho-ERK."}, {"sent_idx": 8, "char_start": 1312, "char_end": 1490, "sent_text": "A combination treatment of a pan-RAF inhibitor (LY3009120) and a MEK inhibitor (trametinib) effectively suppressed phospho-ERK and inhibited growth of OCIP256 XDO and PDX models."}, {"sent_idx": 9, "char_start": 1491, "char_end": 1619, "sent_text": "PDAC/duodenal adenocarcinoma have high success rates forming PDX/organoid and retaining their phenotypic and genotypic features."}, {"sent_idx": 10, "char_start": 1620, "char_end": 1701, "sent_text": "These models may be effective tools to evaluate novel drug combination therapies."}], "PMID_31883794": [{"sent_idx": 0, "char_start": 0, "char_end": 132, "sent_text": "Glioblastomas exhibit vast inter- and intra-tumoral heterogeneity, complicating the development of effective therapeutic strategies."}, {"sent_idx": 1, "char_start": 133, "char_end": 280, "sent_text": "Current in\u00a0vitro models are limited in preserving the cellular and mutational diversity of parental tumors and require a prolonged generation time."}, {"sent_idx": 2, "char_start": 281, "char_end": 526, "sent_text": "Here, we report methods for generating and biobanking patient-derived glioblastoma organoids (GBOs) that recapitulate the histological features, cellular diversity, gene expression, and mutational profiles of their corresponding parental tumors."}, {"sent_idx": 3, "char_start": 527, "char_end": 665, "sent_text": "GBOs can be generated quickly with high reliability and exhibit rapid, aggressive infiltration when transplanted into adult rodent brains."}, {"sent_idx": 4, "char_start": 666, "char_end": 875, "sent_text": "We further demonstrate the utility of GBOs to test personalized therapies by correlating GBO mutational profiles with responses to specific drugs and by modeling chimeric antigen receptor T\u00a0cell immunotherapy."}, {"sent_idx": 5, "char_start": 876, "char_end": 1028, "sent_text": "Our studies show that GBOs maintain many key features of glioblastomas and can be rapidly deployed to investigate patient-specific treatment strategies."}, {"sent_idx": 6, "char_start": 1029, "char_end": 1138, "sent_text": "Additionally, our live biobank establishes a rich resource for basic and translational glioblastoma research."}], "PMID_30017245": [{"sent_idx": 0, "char_start": 0, "char_end": 171, "sent_text": "Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse."}, {"sent_idx": 1, "char_start": 172, "char_end": 381, "sent_text": "To gain insights into the biology of MRD, we applied single-cell RNA sequencing to malignant cells isolated from BRAF mutant patient-derived xenograft melanoma cohorts exposed to concurrent RAF/MEK-inhibition."}, {"sent_idx": 2, "char_start": 382, "char_end": 545, "sent_text": "We identified distinct drug-tolerant transcriptional states, varying combinations of which co-occurred within MRDs from PDXs and biopsies of patients on treatment."}, {"sent_idx": 3, "char_start": 546, "char_end": 669, "sent_text": "One of these exhibited a neural crest stem cell (NCSC) transcriptional program largely driven by the nuclear receptor RXRG."}, {"sent_idx": 4, "char_start": 670, "char_end": 769, "sent_text": "An RXR antagonist mitigated accumulation of NCSCs in MRD and delayed the development of resistance."}, {"sent_idx": 5, "char_start": 770, "char_end": 890, "sent_text": "These data identify NCSCs as key drivers of resistance and illustrate the therapeutic potential of MRD-directed therapy."}, {"sent_idx": 6, "char_start": 891, "char_end": 1091, "sent_text": "They also highlight how gene regulatory network architecture reprogramming may be therapeutically exploited to limit cellular heterogeneity, a key driver of disease progression and therapy resistance."}], "PMID_32075943": [{"sent_idx": 0, "char_start": 0, "char_end": 180, "sent_text": "Topoisomerase I (TOP1) inhibitors trap TOP1 cleavage complexes resulting in DNA double-strand breaks (DSBs) during replication, which are repaired by homologous recombination (HR)."}, {"sent_idx": 1, "char_start": 181, "char_end": 347, "sent_text": "Triple-negative breast cancer (TNBC) could be eligible for TOP1 inhibitors given the considerable proportion of tumors with a defect in HR-mediated repair (BRCAness)."}, {"sent_idx": 2, "char_start": 348, "char_end": 437, "sent_text": "The TOP1 inhibitor irinotecan was tested in 40 patient-derived xenografts (PDXs) of TNBC."}, {"sent_idx": 3, "char_start": 438, "char_end": 717, "sent_text": "BRCAness was determined with a single-nucleotide polymorphism (SNP) assay, and expression of Schlafen family member 11 (SLFN11) and retinoblastoma transcriptional corepressor 1 (RB1) was evaluated by real-time polymerase chain reaction (RT-PCR) and immunohistochemistry analyses."}, {"sent_idx": 4, "char_start": 718, "char_end": 957, "sent_text": "In addition, the combination of irinotecan and the ataxia telangiectasia and Rad3-related protein (ATR) inhibitor VE-822 was tested in SLFN11-negative PDXs, and two clinical non-camptothecin TOP1 inhibitors (LMP400 and LMP776) were tested."}, {"sent_idx": 5, "char_start": 958, "char_end": 1022, "sent_text": "Thirty-eight percent of the TNBC models responded to irinotecan."}, {"sent_idx": 6, "char_start": 1023, "char_end": 1250, "sent_text": "BRCAness combined with high SLFN11 expression and RB1 loss identified highly sensitive tumors, consistent with the notion that deficiencies in cell cycle checkpoints and DNA repair result in high sensitivity to TOP1 inhibitors."}, {"sent_idx": 7, "char_start": 1251, "char_end": 1428, "sent_text": "Treatment by the ATR inhibitor VE-822 increased sensitivity to irinotecan in SLFN11-negative PDXs and abolished irinotecan-induced phosphorylation of checkpoint kinase 1 (CHK1)."}, {"sent_idx": 8, "char_start": 1429, "char_end": 1547, "sent_text": "LMP400 (indotecan) and LMP776 (indimitecan) showed high antitumor activity in BRCA1-mutated or BRCAness-positive PDXs."}, {"sent_idx": 9, "char_start": 1548, "char_end": 1682, "sent_text": "Last, low SLFN11 expression was associated with poor survival in 250 patients with TNBC treated with anthracycline-based chemotherapy."}, {"sent_idx": 10, "char_start": 1683, "char_end": 1753, "sent_text": "In conclusion, a substantial proportion of TNBC respond to irinotecan."}, {"sent_idx": 11, "char_start": 1754, "char_end": 1901, "sent_text": "BRCAness, high SLFN11 expression, and RB1 loss are highly predictive of response to irinotecan and the clinical indenoisoquinoline TOP1 inhibitors."}], "PMID_30146332": [{"sent_idx": 0, "char_start": 0, "char_end": 123, "sent_text": "Personalized cancer therapy targeting somatic mutations in patient tumors is increasingly being incorporated into practice."}, {"sent_idx": 1, "char_start": 124, "char_end": 282, "sent_text": "Other therapeutic vulnerabilities resulting from changes in gene expression due to tumor specific epigenetic perturbations are progressively being recognized."}, {"sent_idx": 2, "char_start": 283, "char_end": 386, "sent_text": "These genomic and epigenomic changes are ultimately manifest in the tumor proteome and phosphoproteome."}, {"sent_idx": 3, "char_start": 387, "char_end": 557, "sent_text": "We integrated transcriptomic, epigenomic, and proteomic/phosphoproteomic data to elucidate the cellular origins and therapeutic vulnerabilities of rhabdomyosarcoma (RMS)."}, {"sent_idx": 4, "char_start": 558, "char_end": 656, "sent_text": "We discovered that alveolar RMS occurs further along the developmental program than embryonal RMS."}, {"sent_idx": 5, "char_start": 657, "char_end": 793, "sent_text": "We also identified deregulation of the RAS/MEK/ERK/CDK4/6, G2/M, and unfolded protein response pathways through our integrated analysis."}, {"sent_idx": 6, "char_start": 794, "char_end": 945, "sent_text": "Comprehensive preclinical testing revealed that targeting the WEE1 kinase in the G2/M pathway is the most effective approach in\u00a0vivo for high-risk RMS."}], "PMID_29458007": [{"sent_idx": 0, "char_start": 0, "char_end": 122, "sent_text": "High-grade serous ovarian cancer (HGSC) is the leading cause of morbidity and mortality from gynecologic malignant tumors."}, {"sent_idx": 1, "char_start": 123, "char_end": 268, "sent_text": "Overall survival remains low because of the nearly ubiquitous emergence of platinum resistance and the paucity of effective next-line treatments."}, {"sent_idx": 2, "char_start": 269, "char_end": 434, "sent_text": "Current cell culture-based models show limited similarity to HGSC and are therefore unreliable predictive models for preclinical evaluation of investigational drugs."}, {"sent_idx": 3, "char_start": 435, "char_end": 588, "sent_text": "This deficiency could help explain the low overall rate of successful drug development and the decades of largely unchanged approaches to HGSC treatment."}, {"sent_idx": 4, "char_start": 589, "char_end": 797, "sent_text": "We used gene expression, copy number variation, and exome sequencing analyses to credential HGSC patient-derived xenografts (PDXs) as effective preclinical models that recapitulate the features of human HGSC."}, {"sent_idx": 5, "char_start": 798, "char_end": 876, "sent_text": "Mice bearing PDXs were also treated with standard-of-care carboplatin therapy."}, {"sent_idx": 6, "char_start": 877, "char_end": 971, "sent_text": "PDXs showed similar sensitivity to carboplatin as the patient's tumor at the time of sampling."}, {"sent_idx": 7, "char_start": 972, "char_end": 1138, "sent_text": "PDXs also recapitulated the diversity of genomic alterations (copy number variation and mutation profiles) previously described in large data sets that profiled HGSC."}, {"sent_idx": 8, "char_start": 1139, "char_end": 1263, "sent_text": "Furthermore, mRNA profiling showed that the PDXs represent all HGSC subtypes with the exception of the immunoreactive group."}, {"sent_idx": 9, "char_start": 1264, "char_end": 1482, "sent_text": "Credentialing of PDX models of HGSC should aid progress in HGSC research by providing improved preclinical models of HGSC that can be used to test novel targets and more accurately evaluate their likelihood of success."}], "PMID_35508177": [{"sent_idx": 0, "char_start": 0, "char_end": 132, "sent_text": "Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown to model clinical response to cancer therapy."}, {"sent_idx": 1, "char_start": 133, "char_end": 240, "sent_text": "However, it remains challenging to use these models to guide timely clinical decisions for cancer patients."}, {"sent_idx": 2, "char_start": 241, "char_end": 511, "sent_text": "Here, we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of micro-organospheres (MOSs) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology."}, {"sent_idx": 3, "char_start": 512, "char_end": 762, "sent_text": "A clinical study of recently diagnosed metastatic colorectal cancer (CRC) patients using an MOS-based precision oncology pipeline reliably assessed tumor drug response within 14\u00a0days, a timeline suitable for guiding treatment decisions in the clinic."}, {"sent_idx": 4, "char_start": 763, "char_end": 997, "sent_text": "Furthermore, MOSs capture original stromal cells and allow T\u00a0cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T\u00a0cell therapies on patient tumors."}], "PMID_30395907": [{"sent_idx": 0, "char_start": 0, "char_end": 159, "sent_text": "Lead discovery in osteosarcoma has been hampered by the lack of new agents, limited representative clinical samples and paucity of accurate preclinical models."}, {"sent_idx": 1, "char_start": 160, "char_end": 423, "sent_text": "We developed orthotopic patient-derived xenografts (PDXs) that recapitulated the molecular, cellular and histologic features of primary tumors, and screened PDX-expanded short-term cultures and commercial cell lines of osteosarcoma against focused drug libraries."}, {"sent_idx": 2, "char_start": 424, "char_end": 592, "sent_text": "Osteosarcoma cells were most sensitive to HDAC, proteasome, and combination PI3K/MEK and PI3K/mTOR inhibitors, and least sensitive to PARP, RAF, ERK and MEK inhibitors."}, {"sent_idx": 3, "char_start": 593, "char_end": 705, "sent_text": "Correspondingly, PI3K signaling pathway genes were up-regulated in metastatic tumors compared to primary tumors."}, {"sent_idx": 4, "char_start": 706, "char_end": 855, "sent_text": "In combinatorial screens, as a class, HDAC inhibitors showed additive effects when combined with standard-of-care agents gemcitabine and doxorubicin."}, {"sent_idx": 5, "char_start": 856, "char_end": 1109, "sent_text": "This lead discovery strategy afforded a means to perform high-throughput drug screens of tumor cells that accurately recapitulated those from original human tumors, and identified classes of novel and repurposed drugs with activity against osteosarcoma."}], "PMID_32884042": [{"sent_idx": 0, "char_start": 0, "char_end": 170, "sent_text": "Esophageal adenocarcinoma has few known recurrent mutations and therefore robust, reliable and reproducible patient-specific models are needed for personalized treatment."}, {"sent_idx": 1, "char_start": 171, "char_end": 343, "sent_text": "Patient-derived organoid culture is a strategy that may allow for the personalized study of esophageal adenocarcinoma and the development of personalized induction therapy."}, {"sent_idx": 2, "char_start": 344, "char_end": 466, "sent_text": "We therefore developed a protocol to establish EAC organoids from endoscopic biopsies of na\u00efve esophageal adenocarcinomas."}, {"sent_idx": 3, "char_start": 467, "char_end": 666, "sent_text": "Histologic characterization and molecular characterization of organoids by whole exome sequencing demonstrated recapitulation of the tumors' histology and genomic (~\u200960% SNV overlap) characteristics."}, {"sent_idx": 4, "char_start": 667, "char_end": 850, "sent_text": "Drug testing using clinically appropriate chemotherapeutics and targeted therapeutics showed an overlap between the patient's tumor response and the corresponding organoids' response."}, {"sent_idx": 5, "char_start": 851, "char_end": 965, "sent_text": "Furthermore, we identified Barrett's esophagus epithelium as a potential source of organoid culture contamination."}, {"sent_idx": 6, "char_start": 966, "char_end": 1109, "sent_text": "In conclusion, organoids can be robustly cultured from endoscopic biopsies of esophageal adenocarcinoma and recapitulate the originating tumor."}, {"sent_idx": 7, "char_start": 1110, "char_end": 1221, "sent_text": "This model demonstrates promise as a tool to better personalize therapy for esophageal adenocarcinoma patients."}], "PMID_34027491": [{"sent_idx": 0, "char_start": 0, "char_end": 134, "sent_text": "Tumor organoids and patient-derived orthotopic xenografts (PDOXs) are some of the most valuable pre-clinical tools in cancer research."}, {"sent_idx": 1, "char_start": 135, "char_end": 242, "sent_text": "In this protocol, we describe efficient derivation of organoids and PDOX models from glioma patient tumors."}, {"sent_idx": 2, "char_start": 243, "char_end": 355, "sent_text": "We provide detailed steps for organoid culture, intracranial implantation, and detection of tumors in the brain."}, {"sent_idx": 3, "char_start": 356, "char_end": 449, "sent_text": "We further present technical adjustments for standardized functional assays and drug testing."}, {"sent_idx": 4, "char_start": 450, "char_end": 556, "sent_text": "For complete details on the use and execution of this protocol, please refer to Golebiewska et\u00a0al. (2020)."}], "PMID_30380421": [{"sent_idx": 0, "char_start": 0, "char_end": 114, "sent_text": "Overall survival remains very poor for patients diagnosed as having head and neck squamous cell carcinoma (HNSCC)."}, {"sent_idx": 1, "char_start": 115, "char_end": 233, "sent_text": "Identification of additional biomarkers and novel therapeutic strategies are important for improving patient outcomes."}, {"sent_idx": 2, "char_start": 234, "char_end": 488, "sent_text": "Patient-derived xenografts (PDXs), generated by implanting fresh tumor tissue directly from patients into immunodeficient mice, recapitulate many of the features of their corresponding clinical cancers, including histopathological and molecular profiles."}, {"sent_idx": 3, "char_start": 489, "char_end": 719, "sent_text": "Using a large collection of PDX models of HNSCC, we demonstrate that rapid engraftment into immunocompromised mice is highly prognostic and show that genomic deregulation of the G1/S checkpoint pathway correlates with engraftment."}, {"sent_idx": 4, "char_start": 720, "char_end": 839, "sent_text": "Furthermore, CCND1 and CDKN2A genomic alterations are predictive of response to the CDK4and CDK6 inhibitor abemaciclib."}, {"sent_idx": 5, "char_start": 840, "char_end": 1120, "sent_text": "Overall, our study supports the pursuit of CDK4 and CDK6 inhibitors as a therapeutic strategy for a substantial proportion of HNSCC patients and demonstrates the potential of using PDX models to identify targeted therapies that will benefit patients who have the poorest outcomes."}]}